Beatrice Heim1, Atbin Djamshidian2, Anna Heidbreder1, Ambra Stefani1, Laura Zamarian1, Marie-Theres Pertl1, Elisabeth Brandauer1, Margarete Delazer1, Klaus Seppi1, Werner Poewe1, Birgit Högl1. 1. From the Departments of Neurology (B. Heim, A.D., A.H., A.S., L.Z., M.-T.P., E.B., M.D., K.S., W.P., B. Högl) and Psychology (M.-T.P.), Medical University Innsbruck, Austria; and Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies (A.D.), University of London, UK. 2. From the Departments of Neurology (B. Heim, A.D., A.H., A.S., L.Z., M.-T.P., E.B., M.D., K.S., W.P., B. Högl) and Psychology (M.-T.P.), Medical University Innsbruck, Austria; and Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies (A.D.), University of London, UK. atbin.djamshidian-tehrani@i-med.ac.at.
Abstract
OBJECTIVES: To assess the frequency of impulse control disorders (ICDs) in patients with restless legs syndrome (RLS) with and without augmentation under dopaminergic therapy in a case-control study. Augmentation and ICDs are both serious complications of dopaminergic treatment of RLS but little is known about possible associations between these drug-induced disorders. METHODS: In total, 58 patients with idiopathic RLS diagnosed according to the International Restless Legs Syndrome Study Group criteria were recruited. Of these, 35 patients had augmentation. The frequency of ICD symptoms was assessed using semi-structural interviews. RESULTS: Demographic variables did not differ between patients with RLS with and without augmentation but those with augmentation took higher dopaminergic medication than patients without augmentation. Twenty-three patients with RLS (39.7%) had ICD symptoms, with 12 patients (20.7%) having definitive ICDs. Patients with augmentation had an increased risk of expressing ICD symptoms (p = 0.007, odds ratio 5.64, 95% confidence interval 1.59-20.02). CONCLUSIONS: Patients with RLS with augmentation have an almost 6-fold increased risk of exhibiting ICD symptoms. This implies that augmentation and ICDs are related and may share a common pathophysiology. Moreover, our results have clinical implications, suggesting that patients with RLS with augmentation should be screened for ICD symptoms.
OBJECTIVES: To assess the frequency of impulse control disorders (ICDs) in patients with restless legs syndrome (RLS) with and without augmentation under dopaminergic therapy in a case-control study. Augmentation and ICDs are both serious complications of dopaminergic treatment of RLS but little is known about possible associations between these drug-induced disorders. METHODS: In total, 58 patients with idiopathic RLS diagnosed according to the International Restless Legs Syndrome Study Group criteria were recruited. Of these, 35 patients had augmentation. The frequency of ICD symptoms was assessed using semi-structural interviews. RESULTS: Demographic variables did not differ between patients with RLS with and without augmentation but those with augmentation took higher dopaminergic medication than patients without augmentation. Twenty-three patients with RLS (39.7%) had ICD symptoms, with 12 patients (20.7%) having definitive ICDs. Patients with augmentation had an increased risk of expressing ICD symptoms (p = 0.007, odds ratio 5.64, 95% confidence interval 1.59-20.02). CONCLUSIONS:Patients with RLS with augmentation have an almost 6-fold increased risk of exhibiting ICD symptoms. This implies that augmentation and ICDs are related and may share a common pathophysiology. Moreover, our results have clinical implications, suggesting that patients with RLS with augmentation should be screened for ICD symptoms.
Authors: Hayley Worth; Daniel V O'Hara; Neeru Agarwal; David Collister; Frank Brennan; Brendan Smyth Journal: Clin J Am Soc Nephrol Date: 2022-01-05 Impact factor: 10.614
Authors: Beatrice Heim; Marie-Theres Pertl; Ambra Stefani; Anna Heidbreder; Laura Zamarian; Elisabeth Brandauer; Bruno Averbeck; Margarete Delazer; Klaus Seppi; Birgit Högl; Werner Poewe; Atbin Djamshidian Journal: Ann Clin Transl Neurol Date: 2018-01-30 Impact factor: 4.511
Authors: Beatrice Heim; Marina Peball; Carsten Saft; Sarah Maria von Hein; Philipp Ellmerer; Johanna Maria Piater; Klaus Seppi; Atbin Djamshidian Journal: Brain Behav Date: 2020-09-26 Impact factor: 2.708
Authors: Philipp Ellmerer; Beatrice Heim; Ambra Stefani; Marina Peball; Mario Werkmann; Evi Holzknecht; Melanie Bergmann; Elisabeth Brandauer; Martin Sojer; Laura Zamarian; Margarete Delazer; Klaus Seppi; Birgit Högl; Werner Poewe; Atbin Djamshidian Journal: Ann Clin Transl Neurol Date: 2020-08-12 Impact factor: 4.511